Vera Therapeutics, Inc. (VERA)
NasdaqGM · USD · Healthcare · Biotechnology
$28.30 (+1.11%) as of
Key statistics
- Market cap
- 2.04B
- Forward P/E
- -6.66
- EPS (TTM)
- -5.47
- Dividend yield
- 0.00%
- 52-week range
- 23.05 – 56.05
- Beta
- 1.05
- Profit margin
- 0.00%
- Analyst target
- $74.20
- Volume
- 1.17M
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Brisbane, CA, United States
- Employees
- 361
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.